On September 15, Insmed fell 5.04% in regular trading, trading at $119.99/share, with Turnover of $39.03 million.
Within the Biotechnology sector where Insmed belongs, the overall sector showed broad weakness. Among individual stocks, Ascendis Pharma A/S down 11.21%, Moderna, Inc. down 2.26%, Vera Therapeutics, Inc. down 1.80%, Amgen down 1.40%, AbbVie down 0.68%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)